The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma

Rezahosseini, Omid; Hanaei, Sara; Hamadani, Mehdi; Keshavarz-Fathi, Mahsa; Rezaei, Nima

doi:10.1080/08830185.2017.1405396

Cited by 4 publications

(2 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are relatively safe, especially human mAbs that have evolved in humans at high concentrations to fight diseases and long-term use may not lead to toxicities [86]. In non-Hodgkin lymphoma (NHLs), Brentuximabvedotin (Adcetris), Ibritumomabtiuxetan (Zevalin) and rituximab (Rituxan), has been used for treatment of NHLs and showed promising results [87]. nAb therapy has been studied in several cancers including virusassociated cancers [88].…”

Section: Neutralizing Monoclonal Antibody-based Immunotherapiesmentioning

confidence: 99%

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Joseph,

Sandel,

Kulkarni

et al. 2023

Pathogens

View full text Add to dashboard Cite

Infectious agents, notably viruses, can cause or increase the risk of cancer occurrences. These agents often disrupt normal cellular functions, promote uncontrolled proliferation and growth, and trigger chronic inflammation, leading to cancer. Approximately 20% of all cancer cases in humans are associated with an infectious pathogen. The International Agency for Research on Cancer (IARC) recognizes seven viruses as direct oncogenic agents, including Epstein–Barr Virus (EBV), Kaposi’s Sarcoma-associated herpesvirus (KSHV), human T-cell leukemia virus type-1 (HTLV-1), human papilloma virus (HPV), hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus type 1 (HIV-1). Most viruses linked to increased cancer risk are typically transmitted through contact with contaminated body fluids and high-risk behaviors. The risk of infection can be reduced through vaccinations and routine testing, as well as recognizing and addressing risky behaviors and staying informed about public health concerns. Numerous strategies are currently in pre-clinical phases or undergoing clinical trials for targeting cancers driven by viral infections. Herein, we provide an overview of risk factors associated with increased cancer incidence in people living with HIV (PLWH) as well as other chronic viral infections, and contributing factors such as aging, toxicity from ART, coinfections, and comorbidities. Furthermore, we highlight both antibody- and cell-based strategies directed against virus-induced cancers while also emphasizing approaches aimed at discovering cures or achieving complete remission for affected individuals.

show abstract

Section: Neutralizing Monoclonal Antibody-based Immunotherapiesmentioning

confidence: 99%

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Joseph,

Sandel,

Kulkarni

et al. 2023

Pathogens

View full text Add to dashboard Cite

show abstract

“…Rituximab, an anti-CD20 chimeric antibody, was approved in 1997 for treating non-Hodgkin B cell lymphoma. Rituximab interacts with CD20 antigen expressed on B cell tumors and then eliminates malignant cells through an effective immune response [15]. Ibritumab (Zevalin®), Obinutuzumab (Gazyva®), and Ofatumumab (Arzera®) are the other mAbs against CD20 antigen [16].…”

Section: Applications Of Monoclonal Antibodies: Therapeutic and Diagnostic Uses 41 Therapeutic Applications Of Mabs In Cancer Therapymentioning

confidence: 99%

Introduction on Monoclonal Antibodies

Sadeghalvad¹,

Rezaei²

2021

Monoclonal Antibodies

Self Cite

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are a group of antibodies produced by identical clones of B lymphocytes against a particular antigen. mAbs are identical in several properties such as protein sequence, antigen-binding site region, binding affinity for their targets, and identical downstream functional effects. These characteristics of mAbs highlight their differences with the polyclonal antibodies which have heterogenous activities and recognize different epitopes on an antigen. Murine mAbs was the first generation of mAbs developed by hybridoma technology however, because of their murine origin, they can trigger the anti-mouse antibody response in the host which could accelerate mAb clearance and undesirable allergic reactions upon repeated administration. This issue was resolved by developing engineering methods toward producing less immunologic chimeric or humanized antibodies. mAbs applications have become a novel way of targeting antigens in a wide variety of diseases such as autoimmunity, malignancies, and asthma. In addition, high specificity and high affinity binding properties of mAbs make them effective biological reagents in immunodiagnostic assays. They can be used in diagnosis of infectious diseases and detection of certain antigens or in serological assessments for detection of antibodies against a certain antigen. This chapter summarizes the general properties of mAbs, their production processes, and their important diagnostic and therapeutic applications.

show abstract

In this issue: Role of immune cells and molecules in rheumatoid arthritis pathogenesis and cancer immunotherapy

Kumar

Bot

2018

International Reviews of Immunology

View full text Add to dashboard Cite

The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma

Cited by 4 publications

References 90 publications

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS

Introduction on Monoclonal Antibodies

In this issue: Role of immune cells and molecules in rheumatoid arthritis pathogenesis and cancer immunotherapy

Contact Info

Product

Resources

About